BiTEs bring T cells into proximity to leukemic cells being studied in many clinical trial but not yet approved for AML or MDS including AMG 330 (bispecific CD3/CD33 antibody), flotetuzumab, XmAb14045 (bispecific CD3/CD123 antibodies), MCLA-117 (bispecific CD3/CLL1 antibody), and AMV564 (bispecific CD3/CD33 T cell engager). Here, CD33 is linked to myelodysplastic syndrome.